相关实验视频

Updated: Jun 13, 2025

Author Spotlight: Investigating the Blood Glucose Homeostasis in Murine Brain Using a Cost-Effective Hyperglycemic And Hypoglycemic Clamp Technique

Author Spotlight: Investigating the Blood Glucose Homeostasis in Murine Brain Using a Cost-Effective Hyperglycemic And Hypoglycemic Clamp Technique

Published on: January 26, 2024

具有高胰岛素载荷能力的葡萄糖敏感微针贴片,用于老鼠和迷你猪的长期血糖控制

Shiqi Wang¹, Changwei Yang¹, Wentao Zhang¹

¹State Key Laboratory of Advanced Drug Delivery and Release Systems, Key Laboratory for Advanced Drug Delivery Systems of Zhejiang Province, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.

|September 11, 2024

概括

这项研究引入了一种用于糖尿病管理的新型微针贴片. 该贴片以响应葡萄糖的方式提供胰岛素,提供长达48小时的持续血糖控制.

科学领域:

生物材料科学生物材料科学
纳米技术纳米技术
内分泌学在内分泌学.

背景情况:

透皮微针系统为糖尿病管理提供最小侵入性葡萄糖反应性胰岛素输送.
传统的微针在药物负载能力方面存在局限性,这阻碍了长期的治疗效果和临床转化.
实现持续的正常血糖需要高效的胰岛素输送系统,具有高药物负载和精确的葡萄糖响应.

研究的目的:

开发一种具有高胰岛素负载能力和葡萄糖反应释放机制的微针贴片.
为了克服传统微针在长期血糖调节方面的局限性.
在糖尿病的临床前模型中证明新型微针贴片的疗效.

主要方法:

微针贴片的制造,其中包括固体胰岛素粉芯和对葡萄糖敏感的聚合物外.
利用葡萄糖-酸盐复合物的形成来触发胰岛素释放以应对高血糖症.
微针贴片在1型糖尿病小鼠和迷你猪体内测试,以评估葡萄糖调节的有效性和持续时间.

主要成果:

开发的微针贴片实现了高胰岛素负载能力,超过70%的重量.
这种对葡萄糖敏感的外在暴露于高度葡萄糖时促进了胰岛素的加速释放.
在1型糖尿病小鼠和小猪中,长达48小时的持续血糖调节被证明是有效的.

结论:

新型的微针贴片设计有效地解决了传统系统的低药物载荷能力.
这种对葡萄糖反应的系统为长期糖尿病管理提供了一种有前途的微创方法.
在动物模型中证明的疗效表明,在治疗1型糖尿病方面有临床转化潜力.

关键词:

糖尿病糖尿病患者糖尿病患者药物输送是药物输送的过程.葡萄糖反应敏感的葡萄糖在这种情况下,胰岛素胰岛素胰岛素.微针是一种微针.

更多相关视频

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

Simple Continuous Glucose Monitoring in Freely Moving Mice

Simple Continuous Glucose Monitoring in Freely Moving Mice

Published on: February 24, 2023

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...